Mereo BioPharma Group (MREO) Expected to Announce Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO) will likely be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Mereo BioPharma Group to post earnings of $0.02 per share for the quarter.

Mereo BioPharma Group Price Performance

NASDAQ:MREO opened at $2.49 on Tuesday. Mereo BioPharma Group has a 12 month low of $2.25 and a 12 month high of $5.02. The business’s fifty day moving average price is $2.77 and its 200 day moving average price is $3.54.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Monday, January 13th. Jefferies Financial Group assumed coverage on shares of Mereo BioPharma Group in a research note on Friday, December 6th. They issued a “buy” rating and a $7.00 price target on the stock. Lifesci Capital assumed coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $7.83.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.